KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Operations (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Cash from Operations for 16 consecutive years, with 163555000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 272.78% year-over-year to 163555000.0, compared with a TTM value of 524080000.0 through Dec 2025, up 6405.1%, and an annual FY2025 reading of 524080000.0, up 6405.1% over the prior year.
  • Cash from Operations was 163555000.0 for Q4 2025 at Alnylam Pharmaceuticals, down from 325109000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 359412000.0 in Q3 2023 and bottomed at 235660000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 28152150.0, with a median of 104973000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 217.71% in 2024, then soared 643.84% in 2025.
  • Year by year, Cash from Operations stood at 150141000.0 in 2021, then increased by 12.1% to 131978000.0 in 2022, then surged by 77.42% to 29795000.0 in 2023, then plummeted by 217.71% to 94662000.0 in 2024, then soared by 272.78% to 163555000.0 in 2025.
  • Business Quant data shows Cash from Operations for ALNY at 163555000.0 in Q4 2025, 325109000.0 in Q3 2025, and 153730000.0 in Q2 2025.